Reducing Cardiovascular Risk in Patients With Chronic Kidney Disease
Shweta Bansal, MD, FSAN; Charles A Herzog, MD
Chronic kidney disease (CKD) is a growing public health concern. However, the leading cause of morbidity and mortality in CKD is not kidney failure but cardiovascular (CV) disease.
In this panel ReCAP, nephrologist Dr Shweta Bansal of the University of Texas, San Antonio, and cardiologist Dr Charles Herzog from Hennepin Healthcare, Minneapolis, Minnesota, discuss the critical need for a cardiovascular-focused approach to CKD management.
The panelists discuss optimal therapeutic strategies for managing CKM syndrome, including combinations of RAAS inhibitors, SGLT2 inhibitors, nonsteroidal MRAs, and GLP-1 receptor agonists. The experts highlight SGLT2 inhibitors as a key therapy shown to significantly slow CKD progression and reduce CV risk. They also discuss the emerging role of GLP-1 receptor agonists, initially developed for diabetes and weight management, now showing strong benefits in cardiovascular and renal protection.